Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia (Q47194564)

11 January 2018

title

Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia (English)

1 reference

11 January 2018

0 references

1 reference

Xueqin Song

1

1 reference

11 January 2018

Xiaoduo Fan

2

1 reference

11 January 2018

Xue Li

3

1 reference

11 January 2018

Wei Zhang

4

1 reference

11 January 2018

Jinsong Gao

5

1 reference

11 January 2018

Jingping Zhao

6

1 reference

11 January 2018

Amy Harrington

7

1 reference

11 January 2018

Douglas Ziedonis

8

1 reference

11 January 2018

Luxian Lv

9

1 reference

11 January 2018

language of work or name

1 reference

14 December 2013

1 reference

11 January 2018

number of pages

7

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

11 January 2018

volume

231

1 reference

11 January 2018

issue

2

1 reference

11 January 2018

page(s)

319-325

1 reference

11 January 2018

The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

The association of markers of inflammation with weight change in older adults: the Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Cytokines in schizophrenia and the effects of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Inflammation and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Markers of inflammation and weight change in middle-aged adults: results from the prospective MONICA/KORA S3/F3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Inflammation and metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

The metabolic syndrome in schizophrenia: is inflammation a contributing cause?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Altered immune function in unaffected first-degree biological relatives of schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Effects of clozapine on plasma cytokine and soluble cytokine receptor levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

The link between abdominal obesity, metabolic syndrome and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-gamma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3382-4

Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. (DSM-III), Adaptive Functioning in Young Swedish Suicides

21 January 2018

1 reference

12 December 2020

The guidelines for prevention and control of overweight and obesity in Chinese adults

1 reference

12 December 2020

Retrospective reports of weight change and inflammation in the US National Health and Nutrition Examination Survey

1 reference

12 December 2020

Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia

1 reference

12 December 2020

A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?

1 reference

12 December 2020

No evidence for autoimmunity in schizophrenia

1 reference

12 December 2020

Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients

1 reference

12 December 2020

Recent advances in obesity-induced inflammation and insulin resistance

1 reference

12 December 2020

Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype

1 reference

12 December 2020

10.1007/S00213-013-3382-4

Identifiers

DOI

1 reference

11 January 2018

1 reference

11 January 2018